Dose escalation study of intravenous estramustine phosphate in combination with paclitaxel and carboplatin in patients with advanced prostate cancer

Clinical Cancer Research

Volumn 9, Issue 6, 2003, Pages 2098-2107

  Kelly, William Kevin ^a,b   Zhu, Andrew X ^c   Scher, Howard ^a   Curley, Tracey ^a   Fallon, Mary ^a   Slovin, Susan ^a,b   Schwartz, Lawrence ^a   Larson, Steve ^a   Tong, William ^a   Hartley Asp, Beryl ^d   Pellizzoni, Cinzia ^d   Rocchetti, Maurizio ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; DRUG METABOLITE; ESTRAMUSTINE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ANTIGEN DETECTION; AREA UNDER THE CURVE; ARTICLE; BIOTRANSFORMATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MALE; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; THROMBOCYTOPENIA; THROMBOEMBOLISM; TIME SERIES ANALYSIS; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYTOCHROME P-450 ENZYME SYSTEM; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0037501215     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kelly, W., Curley, T., Slovin, S., Heller, G., McCaffrey, J., Bajorin, D., Ciolino, A., Regan, K., Schwartz, M., Kantoff, P., George, D., Oh, W., Smith, M., Kaufman, D., Small, E., Schwartz, L., Larson, S., Tong, W., and Scher, H. Paclitaxel, estramustine phosphate and carboplatin in patients with advanced prostate cancer. J. Clin. Oncol., 19: 44-53, 2001.
2. Canobbio, L., Guarneri, D., Miglietta, L., Decensi, A., Oneto, F., and Boccardo, F. Carboplatin in advanced hormone refractory prostatic cancer patients. Eur. J. Cancer, 29A: 2094-2096, 1993.
3. Ozols, R. F. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Semin. Oncol., 22: 1-17, 1995.
4. Shea, T., Graham, M., Bernard, S., Steagall, A., Wiley, J., Serody, J., Brecher, M., Bentley, S., Johnston, C., Vaisman, A., Chaney, S., Letrent, C., and Brouwer, K. A clinical and pharmacokinetic study of high dose-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor and peripheral stem cells in patients with unresectable or metastatic cancer. Semin. Oncol., 22: 80-85, 1995.
5. Obasaju, C., Johnson, S., Rogatko, A., Kilpatrick, D., Brennan, J., Hamilton, T., Ozols, R. F., O'Dwyer, P., and Gallo, J. M. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin. Cancer Res., 2: 549-552, 1996.
6. Speicher, L. A., Barone, L., and Tew, K. D. Combined antimicrotubule activity of estramustine and Taxol in human prostatic carcinoma cell lines. Cancer Res., 52: 4433-4440, 1992.
7. Speicher, L. A., Barone, L. R., Chapman, A. E., Hudes, G. R., Laing, N., Smith, C. D., and Tew, K. D. P-Glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J. Natl. Cancer Inst. (Bethesda), 86: 688-695, 1994.
8. Gunnarsson, P. O., Forshell, G. P., Fritjofsson, A., and Norlen, B. J. Plasma concentrations of estramustine phosphate and its major metabolites in patients with prostatic carcinoma treated with different doses of estramustine phosphate (estracyt). Scand. J. Urol. Nephrol., 15: 201-206, 1981.
9. Hudes, G., Haas, N., Yeslow, G., Gillon, T., Gunnarsson, P. O., Ellman, M., Nordle, O., Erikson, B., Miller, L., Kopreski, M., Viaro, D., and Hartley-Asp, B. Phase I clinical trial and pharmacologic trial of intravenous estramustine phosphate. J. Clin. Oncol., 20: 115-1127, 2002.
10. Zelefsky, M. J., Kelly, W. K., Scher, H. I., Lee, H., Smart, T., Metz, E., Wolfe, T., Schwartz, L., Fuks, Z., and Leibel, S. A. Results of a Phase II study using estramustine phosphate and vinblastine combination and high dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. J. Clin. Oncol., 18: 1936-1941, 2000.
11. Scher, H. I., Mazumdar, M., and Kelly, W. K. Clinical trials in relapsed prostate cancer: defining the target. J Natl. Cancer Inst. (Bethesda), 88: 1623-1634, 1996.
12. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207, 1981.
13. Imbriaco, M., Larson, S. M., Yeung, H. W., Mawlawi, O. R., Erdi, Y., Venkatraman, E. S., and Scher, H. I. A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin. Cancer Res., 4: 1765-1772, 1998.
14. Sabbatini, P., Larson, S. M., Kremer, A., Zhang, Z. F., Sun, M., Yeung, H., Imbriaco, M., Horak, I., Conolly, M., Ding, C., Ouyang, P., Kelly, W. K., and Scher, H. I. Prognostic significance of extent of disease in bone in patients with androgen independent prostate cancer. J. Clin. Oncol., 17: 948-957, 1999.
15. Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddick, Z. H., Judson, I. R., Gore, M. E., and Wiltshaw, E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 7: 1748-1756, 1989.
16. Longnecker, S. M., Donehower, R. C., and Cates, A. E. High performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a Phase I trial. Cancer Treat. Rep., 71: 53-59, 1987.
17. Schellen, A., Oooms, B., vanGils, M., Halmingh, O., van der Vlis, E., van de Lagemaat, D., and Verheij, E. high throughput on-line solid phase extraction/tandem mass spectrometric determination of paclitaxel in human serum. Rapid Commun. Mass Spectrom., 14: 230-233, 2000.
18. Monsarrat, B., Chatelut, E., Royer, I., Alvinerie, P., Dubois, J., Dezeuse, A., Roche, H., Cros, M., Wright, M., and Canal, P. Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab. Disp., 26: 229-233, 1998.
19. Kang, M. H., Figg, W. D., Ando, Y., Blagosklonny, M. V., Liewehr, D., Fojo, T., and Bates, S. E. The p-glycoprotein antagonist PSC 833 increases the plasma concentration of 6 a-hydroxypaclitaxel, a major metabolite of paclitaxel. Clin. Cancer Res., 7: 1610-1617, 2001.
20. Yamazaki, H., Shaw, P. M., Guengerich, F. P., and Shimada, T. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem. Res. Toxicol., 11: 659-665, 1998.
21. Monshouwer, M., Ings, M., and Rocchetti, M. Method to potentiate the therapeutic efficacy of taxane and derivatives thereof. International Publication Number: WO 01/58455 A1, 2000.
22. Petrylak, D., Nanus, D., Hartley-Asp, B., Shelton, G., Feit, K., Rosmarin, A., Pellizzoni, C., Rocchetti, M., and Cisar, L. Phase I safety and pharmacokinetic study of weekly intravenous Estramustine phosphate and docetaxel in patients with solid tumors. Proceedings of ASCO, 21: 198a.